Profile data is unavailable for this security.
About the company
VIVA Biotech Holdings is a China-based investment holding company. The Company is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The Company operates its businesses mainly in the United States, China, Europe and other regions.
- Revenue in HKD (TTM)2.18bn
- Net income in HKD-347.36k
- Incorporated2008
- Employees2.04k
- LocationVIVA Biotech Holdings735 Ziping RoadZhoupu Town, Pudong New DistrictShanghai 201318ChinaCHN
- Phone+86 2 160893288
- Fax+86 2 158243936
- Websitehttps://www.vivabiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jacobson Pharma Corporation Ltd | 1.47bn | 210.24m | 1.28bn | 1.72k | 5.85 | 0.5343 | 3.64 | 0.8722 | 0.1095 | 0.1391 | 0.7644 | 1.20 | 0.3311 | 2.47 | 6.37 | 851,885.10 | 4.74 | 4.30 | 5.76 | 5.57 | 42.27 | 41.25 | 14.32 | 13.73 | 1.73 | 5.33 | 0.2382 | 40.62 | 15.79 | -0.1401 | 1.31 | -3.05 | 24.06 | 4.10 |
| SinoMab Bioscience Ltd | 2.21m | -218.07m | 1.36bn | 214.00 | -- | 4.51 | -- | 616.66 | -0.2093 | -0.2093 | 0.0021 | 0.2771 | 0.0023 | -- | -- | 10,293.27 | -22.83 | -24.62 | -29.11 | -27.72 | 26.80 | -- | -9,853.75 | -4,451.74 | -- | -81.79 | 0.6339 | -- | -- | -- | 14.45 | -- | 106.81 | -- |
| Ascletis Pharma Inc | 11.02m | -282.34m | 1.42bn | 219.00 | -- | 0.6166 | -- | 129.16 | -0.272 | -0.272 | 0.0106 | 2.35 | 0.0041 | 1.34 | 3.58 | 50,326.80 | -10.47 | -6.43 | -10.85 | -6.64 | -125.17 | 35.67 | -2,561.69 | -243.38 | 24.31 | -- | 0.004 | -- | 4.63 | -19.39 | 54.04 | -- | -20.44 | -- |
| Essex Bio-Technology Ltd | 1.62bn | 262.89m | 1.52bn | 1.46k | 5.96 | 0.7547 | 4.79 | 0.9393 | 0.4499 | 0.4499 | 2.73 | 3.55 | 0.5587 | 2.62 | 2.73 | 1,093,064.00 | 9.07 | 11.20 | 12.10 | 14.73 | 89.78 | 86.01 | 16.24 | 19.77 | 1.61 | -- | 0.1397 | 16.16 | 29.51 | 7.72 | 22.11 | 3.56 | 7.29 | 7.39 |
| Cryofocus Medtech Shanghai Co Ltd | 45.34m | -116.07m | 1.68bn | 370.00 | -- | 13.04 | -- | 37.02 | -0.4854 | -0.4854 | 0.1896 | 0.5382 | 0.1881 | 0.418 | 4,369.58 | 115,672.30 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -80.68 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.18bn | 615.09m | 1.88bn | 1.18k | 3.05 | 0.5254 | 2.70 | 1.59 | 0.4095 | 0.4095 | 0.7845 | 2.38 | 0.2838 | 2.05 | 6.17 | 1,030,850.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
| VIVA Biotech Holdings | 2.18bn | -347.36k | 2.08bn | 2.04k | -- | 0.5020 | 8.19 | 0.9559 | -0.0055 | -0.0055 | 1.06 | 1.93 | 0.2603 | 5.26 | 5.18 | 1,049,316.00 | 0.4017 | -1.39 | 0.5601 | -1.68 | 33.66 | 34.81 | 1.54 | -5.44 | 1.46 | 3.19 | 0.2884 | -- | -9.42 | 59.31 | 78.03 | -- | 31.98 | -- |
| Golden Throat Holdings Group Co Ltd | 1.10bn | 286.42m | 2.37bn | 860.00 | 8.26 | 1.69 | 7.19 | 2.15 | 0.3874 | 0.3874 | 1.49 | 1.90 | 0.4994 | 3.23 | 4.07 | 1,264,845.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Data as of Nov 01 2024. Currency figures normalised to VIVA Biotech Holdings's reporting currency: Hong Kong Dollar HKD
0.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 14.34m | 0.66% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.89m | 0.13% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 1.42m | 0.07% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 929.42k | 0.04% |
| Redwood Wealth Management Group LLCas of 30 Jun 2024 | 272.75k | 0.01% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 155.50k | 0.01% |
| DFA Australia Ltd.as of 31 Aug 2024 | 50.36k | 0.00% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
